EFFICACY OF TOPICAL MINOXIDIL 5% ANDBETAMETHASONE VALERATE 0.1% VERSUS BETAMETHASONE VALERATE 0.1% MONOTHERAPY IN NON-SEGMENTAL VITILIGO
Volume 12 , Issue 3 , September 2022 , Pages 231-238
Authors
Roshna Ahmed Ali 1 ; Ali Mozan Dhahir El-Ethaw 2
1 Dermatology Teaching Center, Ministry of Health, Sulaimani, Kurdistan Region, Iraq.
2 College of Medicine, University of Sulaimani, Kurdistan Region, Iraq.
10.17656/jsmc.10365
Keywords
Abstract
Background
Vitiligo is a common depigmentation disorder of the skin. Circumscribed amelanotic patches characterize
it due to the destruction of melanocytes. It affects 0.5-2.0% of general population. Many combinations of
medical therapies have been studied, but the optimal treatment has yet to be identified.
Objectives
To evaluate the efficacy of topical minoxidil 5% plus betamethasone valerate 0.1% compared to betamethasone
valerate 0.1% monotherapy in the treatment of non-segmental vitiligo
Materials and Methods
This open-label, comparative, therapeutic clinical trial was conducted at the Sulaimani dermatology teaching
center from May 2021 to February 2022. In this trial, 30 patients with non-segmental vitiligo were divided
into two groups, 15 patients each; group A treated with topical minoxidil 5% spray & betamethasone valerate
0.1% cream, and group B was treated with betamethasone valerate 0.1% cream alone, the two regimens were
used twice a day and patients were followed up for three months.
Results
The mean percentage of depigmentation in groups A and B were (21.9%) & (16%), respectively.
Conclusion
Topical minoxidil & betamethasone valerate combination achieved a higher grade of depigmentation,
especially in the vitiligo of the hair-bearing areas of the head & neck. However, there was no significant
difference compared to betamethasone valerate alone (P value = 0.8).
Statistics
- Article view1328
- Downloads51
- Published at21 September 2022
- RIS
- BibTeX
- EndNote
- Mendeley
- APA (7th edition)
- MLA (9th edition)
- Chicago
- Harvard
- IEEE
- Vancouver